Racura Oncology (ASX:RAC) Shares Ease Today: What Are Investors Watching in the HARNESS-1 Trial?

Sonal Goyal

06 November 2026 06:09 PM AEDT

Racura Oncology (ASX:RAC) Shares Ease Today: What Are Investors Watching in the HARNESS-1 Trial?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Racura Oncology (ASX:RAC) traded at A$1.475 during the 6 November 2026 session, down 0.34%.
Racura reported cash of A$30.7 million at 30 September 2026, funding committed activities into mid-CY2028.
The first patient was safely treated with RC220 and osimertinib in the HARNESS-1 trial.

Racura Oncology (ASX:RAC) shares were quoted at A$1.475 during the 6 November 2026 trading session, down 0.34%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the Quarterly Report dated 22 October 2026. Racura is an ASX-listed clinical-stage oncology company developing treatments for cancer.

Latest Developments

Q1 FY27 Quarterly Activities Report (released 22 October 2026)

Racura said its first patient was safely treated with RC220 in combination with osimertinib in the HARNESS-1 trial for EGFR-mutated non-small cell lung cancer, with positive initial safety data. The Phase 1 CPACS trial expanded to South Korea, and ethics approval was received for additional HARNESS-1 sites in New South Wales and Victoria. Cash and equivalents were A$30.7 million, with 80% of spending on Research and Development and drug manufacturing.

About the Company

Racura Oncology is an ASX-listed clinical-stage oncology company headquartered in Australia.

Business Overview

Racura develops oncology drug candidates, with its lead programs in lung cancer trials. Its quarterly reports track trial activity, cash and expenditure.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Clinical-stage oncology companies rely on trial progress, funding and partnerships, and their shares respond to early data.

Risks to Watch

The data so far are initial safety results from a single patient. Trial progress, funding needs and the timing of further data are uncertain.

Catalysts on Watch

Investors may follow further HARNESS-1 patient treatments, data updates and the Phase 1 CPACS trial in South Korea.

Final Takeaways

Racura Oncology (ASX:RAC) traded slightly lower on 6 November 2026 in a session where the health care index eased. Its Q1 FY27 report, dated 22 October 2026, showed trial progress and A$30.7 million of cash.

FAQs

Q: What was the RAC share price on 6 November 2026?

A: Racura shares were quoted at A$1.475 during the trading session, down 0.34%.

Q: What was the cash balance?

A: A$30.7 million at 30 September 2026.

Q: What trial did the first patient join?

A: HARNESS-1, treated with RC220 and osimertinib for EGFR-mutated lung cancer.

Q: How long will the cash fund activities?

A: Into mid-CY2028, according to the company.

Q: Is the session move linked to the report?

A: No. The report was dated 22 October 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.